BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:[ U.S. CDMRP – Autism Research Program Idea Development Award | 
 Research Funding ]
DTSTART;VALUE=DATE:20200428
DTSTAMP:20260407T211022Z
UID:5f27f13d6bb68d4777da3c6d41ca1b07e6746560da2ff91be39c957d
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Autism Research
  Program (ARP) Awards. The ARP Idea Development Award supports the develop
 ment of innovative\, high-risk/high-reward research that could lead to cri
 tical discoveries or major advancements that will accelerate progress in i
 mproving outcomes for individuals with ASD.\n\nImportant aspects of the AR
 P Idea Development Award are as follows:\n\n	Impact: The proposed research
  is expected to make an important and original contribution to advancing t
 he understanding of ASD and ultimately lead to improved outcomes for indiv
 iduals with ASD and their families/caregivers.\n	Innovation: Research deem
 ed innovative may represent a new paradigm\, challenge existing paradigms\
 , look at existing problems from new perspectives\, or exhibit other highl
 y creative qualities\n	Personnel: The study team should have experience in
  ASD research. A biostatistician is encouraged to be included in the study
  team.\n	Research must be based on preliminary data: Although the proposed
  research must have direct relevance to ASD\, the required preliminary dat
 a\, which may include unpublished results from the laboratory of the Princ
 ipal Investigators PI(s)\, research team\, or collaborators named on the a
 pplication\, may be from outside the ASD research field.\n\n\nAll applicat
 ions for ARP funding are highly encouraged to address at least one of the 
 FY20 ARP Areas of Interest\, which are listed at the end of this announcem
 ent.\n\nFunding:        max. $550’000\n\nDuration:      3 year
 s\n\nEligibility: Applicants from international organizations or instituti
 ons are eligible to apply\, and there are no citizenship restrictions. Inv
 estigators at or above the level of Assistant Professor (or equivalent) ar
 e eligible to be named as the Principal Investigator (PI) on the applicati
 on.\n\nHow to Apply: Pre-applications are submitted through the eBRAP plat
 form. They should contain contact information\, a preproposal narrative\, 
 and a list of collaborators and key personnel as suggested on the platform
 . Full applications (by invitation) will be made via a Grants.gov workspac
 e. Full application packages can be downloaded from Grants.gov at any time
 .\n\nPre-Application Deadline: 28-Apr-2020\, 5:00 p.m. EST\nFull Applicati
 on Deadline: 28-Jul-2020\, 11:59 p.m. EST\n\nGrants.gov Funding Opportunit
 y Number: W81XWH-20-ARP-IDA\n\nFurther information\n\n\n	To see the progra
 m announcement\, navigate to the search page on Grants.gov and search for 
 the Opportunity Number W81XWH-20-ARP-IDA\n	For questions about the eBRAP o
 r Grants.gov platforms\, contact the Research Office.\n\n\nFY20 Areas of i
 nterest\n\n\n	Tests of implementation strategies to increase use of eviden
 ce-based practices\n	Development of healthcare provider-focused training o
 r tools to improve healthcare delivery for individuals with ASD across the
  life span and the continuum of care (i.e.\, primary care\, urgent/emergen
 t care\, and disaster relief)\n	Assessment of novel therapeutics using val
 id preclinical models\n	Mechanisms of heterogeneous clinical expression of
  ASD\n	Environmental risk factors\n	Improve diagnosis across the life span
 \n	Factors promoting success in key transitions to independence for indivi
 duals living with ASD\n	Cultural and socioeconomic factors in treatment ef
 ficacy\, delivery\, and access to services\n	Mechanisms underlying sex dif
 ferences in ASD diagnosis\n	Mechanisms underlying conditions co-occurring 
 with ASD (e.g.\, sleep disturbances\, gastrointestinal issues\, inflammati
 on\, aggression\, depression\, anxiety\, attention deficit\, seizures)\n	F
 actors impacting quality of life during geographic relocation\, such as mi
 litary permanent change of station\n	Long-term treatment outcomes from pre
 vious clinical trials for ASD core symptoms or to alleviate co-occurring c
 onditions\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR